// Jul 2026
What Makes a Base Editor Potent and Specific Enough for Therapeutic SNP Correction?
A base editor becomes potent and specific enough for therapeutic SNP correction when the right starting editor is selected from a diverse library, then optimized through parallel engineering of both the editor protein and its guide RNA. For therapeutic development, “close enough” is not enough. The editor must make the intended change efficiently while minimizing bystander and off-target activity.
The Right Starting Editor Creates a Stronger Foundation
You cannot engineer a system to its full potential if you start with a suboptimal tool. Instead of trying to force a single, one-size-fits-all editor to work for every target, the most effective approach begins with screening a diverse library of systems.
By comparing the activity of multiple editor families against a specific pathogenic target, you can identify the one with the most favorable inherent properties. ElevateBio uses this data-driven selection to provide a superior foundation for subsequent engineering.
Parallel Protein Engineering Drives Both Potency and Specificity
Once the best foundational editor is selected, the real work of optimization begins. At ElevateBio, our gene editing platform focuses on engineering the editor’s core protein machinery to boost its performance.
By creating and testing variants, we can significantly increase on-target editing efficiency while simultaneously designing out unwanted activity. This includes minimizing "bystander" edits at adjacent bases and off-target edits elsewhere in the genome, ensuring the editor makes the single, precise change required to address a partner’s disease target.
Guide RNA Optimization Unlocks Additional Performance
The editor protein doesn't work alone. Its guide RNA (gRNA) determines where the editor goes and can strongly influence how efficiently it performs.
Guide RNA optimization provides a complementary path to improve potency. By optimizing the guide backbone sequence, length, and introducing modified bases, ElevateBio further improved editing performance (see the poster with data). In this program, the final optimized guide RNA was 2.5-fold more potent than the initial version, contributing to an overall improvement from ~10% to over 85% correction when combined with the engineered adenine base editor.
Therapeutic SNP Correction Requires Building the Editor Around the Target
Potent and specific base editing is not achieved by choosing an editor off the shelf. At ElevateBio base editors for therapeutic SNP correction are built around the biology, sequence context, and performance requirements of our partner’s specific disease target mutation.
Sean Crosson, Senior Scientist, Translational Biology
As a Senior Scientist at ElevateBio, Sean Crosson engineers and optimizes next-generation gene editing technologies, including base and reverse transcriptase (RT) editors, to develop therapeutics for rare diseases. His background in gene therapy also includes developing novel AAV capsids for ocular diseases at Atsena Therapeutics and during his postdoctoral fellowship.
Sean holds a Ph.D. in Biomedical Science from the University of Florida and dual B.S. degrees in Biology and Chemistry from UNC Chapel Hill. He spends his free time baking, woodworking, and with his family.
